Endo, Inc. (NDOI)
OTCMKTS · Delayed Price · Currency is USD
23.59
+0.49 (2.12%)
Inactive · Last trade price on Jul 31, 2025
Endo, Inc. Revenue
Endo, Inc. had revenue of $392.83M in the quarter ending March 31, 2025, a decrease of -6.36%. This brings the company's revenue in the last twelve months to $1.73B, down -9.52% year-over-year. In the year 2024, Endo, Inc. had annual revenue of $1.76B, down -12.50%.
Revenue (ttm)
1.73B
Revenue Growth
-9.52%
P/S Ratio
1.04
Revenue / Employee
556.31K
Employees
3,116
Market Cap
1.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.76B | -251.38M | -12.50% |
| Dec 31, 2023 | 2.01B | -307.36M | -13.25% |
| Dec 31, 2022 | 2.32B | -674.33M | -22.53% |
| Dec 31, 2021 | 2.99B | 90.13M | 3.10% |
| Dec 31, 2020 | 2.90B | -11.29M | -0.39% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Endo, Inc. News
- 2 months ago - Chiesi Global Rare Diseases Highlights Advancements in Lipodystrophy Research at ENDO 2026 - GlobeNewsWire
- 2 months ago - Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED - GlobeNewsWire
- 2 months ago - Marea Therapeutics Presents Phase 1 Data Supporting Potential Best-in-Disease Profile of MAR002 for the Treatment of Acromegaly at ENDO 2026 - Business Wire
- 2 months ago - Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026 - PRNewsWire
- 2 months ago - Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 - GlobeNewsWire
- 2 months ago - OrsoBio Presents Positive Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and MASLD at ENDO 2026 - Business Wire
- 3 months ago - Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026 - PRNewsWire
- 3 months ago - PRM and Project Endo Launch National University Health Initiative to Improve Early Endometriosis Recognition on College Campuses - GlobeNewsWire